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Multiplesystemtauopathywithpreseniledementia(MSTD)isaninheriteddiseasecausedbya(g)to(a)transition
atposition +3 inintron10 ofTau.Itbelongstothespectrumoffrontotemporaldementiaandparkinsonismlinkedto
chromosome17 with mutations inTau (FTDP-17T).Here we present the longitudinal clinical, neuropsychological,
neuroimaging, neuropathological, biochemicalandgenetic characterization ofthe MSTD family.Presenting signs
were consistent with the behavioural variant of frontotemporal dementia in 17 of 21 patients. Two individuals
presented with an atypical form of progressive supranuclear palsy and two others with either severe postural
imbalanceoranisolatedshort-termmemorydeficit.Memoryimpairmentwaspresent atthe onsetin15patients,
with word finding difficulties and stereotyped speech also being common. Parkinsonism was first noted 3 years
after the onset of symptoms. Neuroimaging showed the most extensive grey matter loss in the hippocampus,
parahippocampal gyrus and frontal operculum/insular cortex of the right hemisphere and, to a lesser extent,
inthe anteriorcingulate gyrus, headofthe caudatenucleus andtheposterolateralorbitofrontalcortexandinsular
cortex bilaterally. Neuropathologically, progressive nerve cell loss, gliosis and coexistent neuronal and/or glial
deposits consistingmostlyof 4-repeattauwerepresentin frontal, cingulate, temporalandinsularcortices, white
matter, hippocampus,parahippocampus,basalganglia, selectedbrainstemnucleiandspinalcord.Tau haplotyping
indicatedthatspecifichaplotypesofthewild-typeallelemayactasmodifiersofdiseasepresentation.Quantitative
neuroimaginghasbeenusedtoanalysetheprogressionofatrophyinaffectedindividualsandforpredictingdisease
onset in an asymptomatic mutation carrier.This multidisciplinary study provides a comprehensive description of
thenaturalhistoryofdiseaseinoneofthelargestknownfamilieswithFTDP-17T.
Keywords: frontotemporaldementia;progressivesupranuclearpalsy;hippocampus;voxel-basedmorphometry;Tau haplotype
Abbreviations: FTD=frontotemporal dementia; MSTD=multiple system tauopathy with presenile dementia;
NFT=neurofibrillary tangle; CA=cornu ammonis
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Introduction
Frontotemporal dementia (FTD) is a clinical syndrome
characterized by behavioural and personality changes, as
well as an impairment of executive function, language and
movement (Brun et al., 1994; Neary et al., 1998; Cairns
et al., 2007). Following the demonstration of linkage to
chromosome 17q21 in a family with an autosomal-
dominant form of FTD (Wilhelmsen et al., 1994),
additional kindreds with inherited FTD linked to the
same region were identified (Petersen et al., 1995; Wijker
et al., 1996; Yamaoka et al., 1996; Bird et al., 1997; Heutink
et al., 1997; Murrell et al., 1997), resulting in the
denomination ‘frontotemporal dementia and parkinsonism
linked to chromosome 17’ (FTDP-17) for this syndrome
(Foster et al., 1997). In 1998, genetic analysis of the Tau
(MAPT) gene on chromosome 17q21 revealed mutations
in affected individuals from 9 of the 13 families orig-
inally linked to chromosome 17 (Poorkaj et al., 1998;
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1998). More recently, mutations in Progranulin (PGRN),
another gene located on chromosome 17q21, have been
associated with frontotemporal lobar degeneration with
tau-negative, ubiquitin-positive inclusions (FTLD-U)
(Baker et al., 2006; Cruts et al., 2006). A mutation in
PGRN has also been found in affected members from three
of the four original FTDP-17 kindreds without Tau
mutations (Mukherjee et al., 2006; Bronner et al., 2007;
Leverenz et al., 2007). Since FTDP-17 can be caused by
mutations in two different genes, FTDP-17T is now being
used to refer to the disease in individuals with a mutation
in Tau. Currently, more than 40 different Tau mutations
have been shown to cause FTDP-17T in individuals from
over 100 families (Goedert and Spillantini, 2006).
During the past 13 years, we have studied the family with
‘multiple system tauopathy with presenile dementia’
(MSTD), one of the original FTDP-17T kindreds (Ghetti
and Farlow, 1994; Murrell et al., 1997; Spillantini et al.,
1997, 1998a, 1998b). The disease in this family is caused by
a (g) to (a) transition at position +3 in intron 10 of Tau,
which results in the overproduction of tau isoforms with 4
microtubule-binding repeats (Spillantini et al., 1998b). In
normal adult human brain, 6 tau proteins are expressed,
with similar levels of 3-repeat and 4-repeat isoforms
(Goedert et al., 1989; Goedert and Jakes, 1990). Here, we
have used clinical, neuropsychological, neuroimaging,
neuropathological, biochemical and genetic data to provide
a longitudinal characterization of the disease in a large
number of individuals from the MSTD family.
Materials and Methods
Subjects
The MSTD pedigree comprises more than 200 individuals spread
over seven generations; 51 individuals are known to have had a
clinical history of frontotemporal dementia (Fig. 1). Clinical
information has been collected on 24 affected family members
(Table 1, Fig. 1). Individuals 1–10 underwent a baseline clinical
and neuropsychological assessment, as well as an annual follow-up
evaluation at the Indiana Alzheimer Disease Center (IADC).
Magnetic resonance imaging (MRI) of the brain was carried out
in eight of these subjects (numbers 1–4, 6–9) and in one
asymptomatic mutation carrier, whose personal data are not
disclosed to preserve anonymity; this individual underwent base-
line and annual follow-up clinical and neuropsychological assess-
ment at the IADC. Clinical information on patients 11–24 was
obtained by interviewing family members and through examina-
tion of clinical records. Data from the neurological examination,
neuropsychological assessment, informant interviews and past
medical records were used to establish a diagnosis of FTD using
standard criteria (Neary et al., 1998). A sub-diagnosis of behavi-
oural variant FTD (bv-FTD) was also established using standard
criteria (McKhann et al., 2001). Pathological studies were carried
out on 14 individuals whose brains were collected at autopsy
(numbers 2, 5, 11, 13–17, 19–24). The spinal cord was dissected
from five individuals (numbers 11, 14, 19, 20, 21). Informed
consent was obtained, either from the patients themselves, or from
their next of kin. This study was approved by the Indiana
University–Purdue University–Indianapolis (IUPUI) Institutional
Review Board.
Clinical assessment
The neurological assessment was done by M.R.F. To obtain
additional information, a structured interview was conducted by a
research nurse with the patients’ caregivers. All patients underwent
extensive neuropsychological testing. Tests were administered
according to standard procedures and interpreted by comparison
with control individuals of similar age and education. The
clinicians were blind to the results of the genetic analysis.
Magnetic resonance imaging
A 1.5 Tesla GE Signa scanner was used to acquire a heavily
T1-weighted, spoiled gradient echo sequence (SPGR; echo
time=8ms, repetition time=35ms, flip angle=30, band-
width=15, matrix=256 128, field of view=24cm, slices=124
ranging from 1.1mm to 1.3mm thicknesses to assure whole brain
coverage). Images were registered at baseline and subsequent
annual follow-up visits. SPM2 was used to conduct optimized
and modulated voxel-based morphometry (VBM) (Ashburner and
Friston, 2000; Good et al., 2001), aided by an automated script
designed by Christian Gaser (http://dbm.neuro.uni-jena.de/
vbm.html). For VBM studies, MRI was performed on seven
MSTD patients [1 year (numbers 4, 6), 2 years (number 1) and
3 years (numbers 2, 3, 8, 9) after disease onset] and 19 age- and
gender-matched controls (patients: four females, three males,
mean age 49.0 4.7 years; controls: 11 females, 8 males, mean age
49.4 6.1 years). Details of the technique are described in
supplementary information, Materials and Methods. Whole
brain volume (WBV) and ventricular volume (VV) normalized
for subject’s head size, as well as two time-point percentage of
brain volume changes (PBVC), were measured from serial MRI
using the SIENAX and SIENA methods (Smith et al., 2002, 2004).
They were assessed during the annual follow-up of the asympto-
matic mutation carrier and symptomatic mutation carriers 1, 2, 3,
7, 9. Standard T2-weighted coronal MRI images were also
acquired.
Neuropathology
The brains of 14 affected individuals were collected. Whole brain
was harvested from five cases and fixed in formalin. For seven
cases, one half of the brain was fixed in formalin and the other
half was frozen. For the remaining two cases, only formalin-fixed,
paraffin-embedded blocks of brain tissue were available. The
spinal cord was collected from five cases. For two cases, the entire
spinal cord was fixed in formalin; for the other three,
representative segments were either fixed or frozen. Tissue
samples for neuropathological studies were obtained from
representative brain regions. The following methods were
used: Weigert’s hematoxylin-eosin, Woelcke–Heidenhain, Bodian,
Gallyas and thioflavin S. For immunohistochemistry, antibodies
against tau, Ab, glial fibrillary acidic protein (GFAP), prion
protein, ubiquitin, CD68 and TAR DNA-binding protein-43
(TDP-43) were used. Tau immunohistochemistry was carried
out using the following phosphorylation-dependent (p), phos-
phorylation-independent and conformation-dependent anti-tau
antibodies: AT8 (Innogenetics, Antwerp, Belgium; 1:400) pS202/
Tauopathy associated with intronic +3 Tau mutation Brain (2008),131,7 2 ^8 9 7 3pT205; PHF1 (1:10) pS396/pS404; AT180 (Innogenetics; 1:500)
pT231; AT270 (Innogenetics, 1:500) pT181; AT100 (Innogenetics,
1:500) pT212/pS214/pT217; 12E8 (Elan Pharmaceuticals, South
San Francisco, California; 1:500) pS262/pS356; CP3 (1:10) pS214;
PG5 (1:10) pS409; BR134 (1:500) against the carboxy-terminus of
tau; RD3 (Upstate, Charlottesville, Virginia; 1:3,000) against
3-repeat tau isoforms; RD4 (Upstate 1:100) against 4-repeat tau
isoforms; Alz50 (1:10) conformational. Additional information is
provided in supplementary information, Materials and Methods.
Genetics
Genetic analysis was carried out on 59 members of the MSTD
kindred. Genomic DNA was extracted from blood (53 individuals)
or brain [fresh and/or formalin-fixed, paraffin-embedded (six
individuals)] using standard protocols (Murrell et al., 1991).
The Tau exon 10 sequence and adjoining intronic sequences were
determined as described (Spillantini et al., 1998b). Standard
amplification reactions were done with 50ng genomic DNA. The
amplified products were gel purified using the Qiaquick Gel
Extraction Kit (Qiagen, Valencia, CA, USA) and asymmetric
amplification performed using the DTCS Quick Start Kit
(Beckman Coulter, Fullerton, CA, USA). Products were loaded
onto a CEQ 2000XL DNA analysis system (Beckman Coulter) and
sequences compared to the known Tau sequence. Tau haplotypes
H1 and H2 were identified by the presence or absence of a 238bp
deletion in intron 9. When DNA was extracted from formalin-
fixed, paraffin-embedded tissue, haplotypes were determined by
assessing single nucleotide polymorphisms in exons 1, 9 and 11
using previously described primers (Baker et al., 1999). Digested
products were separated on a 2% agarose gel. Amplification
products were digested with AluI (SNPs 1 and 11) or MspI
Fig. 1 Pedigree of the kindred with multiple system tauopathy with presenile dementia (MSTD). Affected individuals are distributed over
six consecutive generations.For reasons of confidentiality, not all affected individuals in generations 5 and 6 are shown. Numbers1^24
correspond to the patients with MSTD listed inTable1.
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further analysed by genotyping SNPs rs1467967, rs242557,
rs3785883, rs2471738 and rs7521 (Pittman et al., 2005) using
restriction enzyme digestion of amplified products (DraI for
rs1467967, ApaLI for rs242557, BsaHI for rs3785883, BstEII for
rs2471738 and PstI for rs7521). ApoE genotyping was performed
as described (Hixson and Vernier, 1990).
Biochemistry
Tissue samples from the following brain areas were used: caudate/
putamen, cerebellum, frontal cortex, frontal white matter,
hippocampus and parahippocampus, occipital cortex, occipital
white matter, parietal cortex, parietal white matter, temporal
cortex and thalamus. Sarkosyl-insoluble material was prepared as
described (Goedert et al., 1992) from brain areas of cases number
2 (11 areas), number 5 (nine areas), number 14 (eight areas),
number 17 (nine areas), number 20 (nine areas) and number 21
(eight areas). The spinal cords from numbers 20 and 21 were also
used. In addition, sarkosyl-insoluble material was prepared from
brain areas of two unaffected family members without the +3
mutation (10 areas from each case) and from the frontal cortex
of a case with sporadic Alzheimer’s disease. Sarkosyl-insoluble
material was run on 10% Tris/glycine gels and blotted onto
polyvinylidene fluoride (PVDF) membranes. The blots were
incubated with anti-tau antibodies BR133 (against the amino-
terminus of tau, 1:1000) or BR134 (1:5000) for 1h at room
temperature and developed using enhanced chemiluminescence
(GE Healthcare).
Electron microscopy
Aliquots of the sarkosyl-insoluble dispersed filament preparations
were processed for immunoelectron microscopy, as described
(Crowther, 1991). Micrographs were recorded on a Philips
EM208S microscope at a nominal magnification of  40000.
Antibody BR134 was used at 1:100.
Results
Clinical findings in 10 longitudinally assessed
patients with MSTD
The average age at disease onset in this group of 10 patients
was 47.5 4.9 years (range 39–54 years). Disease duration
in the eight patients who are still alive ranges from 2 to 10
years. Two individuals have died 9 years (number 2) and 15
years (number 5) after developing the disease. Behavioural
changes and/or deficits in executive function constituted the
presenting signs in nine patients (numbers 1–6, 8–10). They
were associated with memory loss in five patients (numbers
4–6, 9, 10) and with memory loss and dysnomia in one
patient (number 1). Subject number 7 presented with
dizziness, hearing loss, tinnitus, pressure-like headache,
up-beating nystagmus and short-term memory loss. He was
diagnosed with Me ´nie `re’s disease. He underwent electro-
nystagmography, electrocochleography and brainstem
Table 1 Demography of the examined MSTD patients
Subject C M R P Gender Age at onset
(years)
Age at death
(years)
Disease duration
(years)
Brain weight
(grams)
MAPT haplotype Apo E
genotype
1+ + F 5 0 N A 6
a NA H1H2 3/3
2+ ++ M 4 5 5 4 9 N A H 2 H 2 3 / 3
3+ + M 4 2 N A 8
a NA H1H2 3/3
4+ + F 5 1 N A 2
a NA H1H2 3/3
5 + + M 54 69 15 1 160 H1H2 3/3
6+ + F 4 6 N A 2
a NA H1H2 2/3
7+ + M 4 5 N A 7
a NA H2H2 3/4
8+ + M 3 9 N A 6
a NA H1H2 3/3
9+ + F 5 3 N A 5
a NA H1H2 3/3
10 + M 50 NA 10
a NA H1H2 NA
1 1 ++M 4 7 4 8 1 N A H 1 H 2 N A
12 + M 42 47 5 NA H1H2 3/3
1 3 ++M 4 8 5 4 6 1 1 5 0 H 1 H 2 N A
1 4 ++F 5 2 5 8 6 1 1 5 0 H 1 H 2 3 / 3
1 5 ++M 5 0 5 7 7 N A H 1 H 2 N A
16 + + M 50 58 8 1000 H2H2 3/3
17 + + F 58 66 8 933 H2H2 3/3
18 + F 58 69 1 1 NA H1H2 2/3
19 + + F 42 54 12 935
b H2H2 NA
20 + + M 52 64 12 1015 H2H2 3/3
2 1 ++F 4 8 6 1 1 3 9 4 5 H 2 H 2 3 / 3
2 2 ++M 5 1 6 6 1 5 N A H 1 H 2 N A
23 + + F 39 59 20 1120
b NA NA
2 4 ++F 4 3 6 4 2 1 N A H 1 H 2 N A
C=subjects clinically examined at the IADC; M=subjects studied by MRI; R=subjects whose clinical information has been
retrospectively collected; P=subjects pathologically examined; NA=not available or not applicable.
aCurrent duration of illness.
bWeighed after formalin fixation.
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and peripheral dysfunction.
Neurobehavioural changes
All 10 patients were diagnosed with frontotemporal
dementia. Disinhibition, social conduct disorder, dysexecu-
tive symptoms, memory impairment and progressive
reduction of speech output were evident in patients affected
for43 years, with the exception of subject number 7, whose
disease course was slower. For this individual, mild short-
term memory problems and slight mental inflexibility were
the only cognitive symptoms during the first 6 years of
disease, with disequilibrium being the most pressing
complaint. More pronounced personality changes and
word-finding difficulties developed later.
Physical signs and symptoms
Findings were compiled from all 10 subjects seen at various
stages of disease (for a more detailed description, see
supplementary information, Table 1). Hypomimia and gait
abnormalities were observed in the third year. Bradykinesia,
symmetric rigidity and postural instability were observed
later in the majority of subjects. Resting tremor was not
present. One subject developed urinary incontinence.
Reduced limb coordination was present in half of the
subjects and was seen as early as the third year. Two
individuals had speech dysfunction, with one individual
developing slurred speech 6 years after the onset of disease,
and the other showing a progressive reduction in speech
volume after 3 years. Dysarthria developed progressively,
culminating in anarthria by the sixth year. Eye movement
abnormalities were noted in 4 patients; they consisted of
square-wave jerks of intrusive saccades during pursuit and/
or vertical gaze reduction. Both abnormalities were first
noted after 5 years of disease. Four individuals suffered
from a severe inversion of the normal sleep-wake cycle
characterized by dramatically reduced nighttime sleep and
increased daytime sleepiness. Two subjects complained of
dizziness and light-headedness. These symptoms were
occasional and mild in one case, but frequent and severely
worsened by rapid movements of the head or after
optokinetic stimulation in the other. One subject developed
dysphagia. Affected individuals displayed mild disinhibition
and reduced concentration during physical examination,
but compliance to physician instructions was preserved
until the later stages of disease.
Neuropsychological assessment
Of the 10 patients, nine received a clinical diagnosis of FTD
at the time of their first assessment. One individual
(number 7) was only diagnosed with FTD during follow-
up. In order to identify the early features of cognitive
dysfunction, a cross-sectional analysis was carried out on
patients with a disease duration of 53 years (n=7).
Comparison with a matched control group is shown in
Table 2. Despite a relatively short duration of disease (mean
of 2 years) and mild dementia (mean MMSE of 25.6), the
MSTD patients had statistically significantly lower scores
than the controls across a broad range of cognitive
domains. The greatest deficits were noted in verbal
memory (Word List Memory, Word List Recall), visual
memory (Visual Reproduction Recall), confrontation
naming (Boston Naming Test) and verbal fluency
[Controlled Oral Word Association (COWA)].
The longitudinal trajectory of cognitive changes was
investigated in the unaffected mutation carrier (see Fig. 2C)
and two patients (numbers 3, 5) (see supplementary
information, Table 2) over a 7- and a 5-year period,
respectively. Subject number 3, when assessed 3 years after
disease onset, showed a subtle weakness in confrontation
naming and a prominent defect in conceptual reasoning
with severe perseveration. Subsequently, impairments in
memory and psychomotor speed became notable. Subject
number 5, when assessed 5 years after the onset of
symptoms, had performances on confrontation naming
and memory below the fifth percentile of healthy controls.
Over time, scores on tests of verbal fluency and
response inhibition fell below threshold of significant
impairment.
Table 2 Neuropsychological performance of MSTD
patients at early disease stage
Affected n=7 Cont rolsn=23 P value
Mean age (years) 48.5 4.4 49.9 6.1 0.58
Gender (% female) 57 .1 69.6 0.54
Elapsed disease
duration (years)
2.1 1.0 n.a. n.a.
MMSE 25.6  2.3 29.0  0.9 50.001
Digit Span 13.0 5.4 16.0  3.5 0.095
Word List Memory 12.9  4.9 23.0 3.5 50.001
Word List Recall 3.7  1.4 8.4  1.2 50.001
Logical Memory 19.4  6.7 30.6 7.4 50.005
Logical Memory
Recall
12.9  7.1 2 7.4   8.2 50.001
Visual Reproduction 28.6  4.4 34.0 3.2 50.005
Visual Reproduction
Recall
12.2  13.0 29.0  5.7 50.001
Boston NamingTest 38.6 12.1 55.6  3.0 (n=22) 50.001
Animal Category 11.3 2.5 21.7 4.3 50.001
COWA 21.6  10.7 39.5  12.0 (n=22)50.005
Block Design 26.0 12.1 35.0  7.4 (n=22) 50.05
Constructional
Praxis
10.3  1.1 10.5  0.7 0.53
Constructional
Praxis Delayed
5.1  3.9 10.9  2.1 50.001
Trail Making A 38.9  14.3 24.6  6.5 50.001
Trail Making B 128.4   60.7 54.9 16.1 50.001
WCSTCategory 3.2  2.6 (n=6) 5 . 4 1.2 (n=2 1 ) 50.01
WCST Pers. Resp. 53.5 56.5 (n=6) 1 0 . 4  8.2 (n=2 1 ) 50.005
Stroop Word 68.0  8.5 (n=6) 96.6 21.6 (n=1 9)50.005
Stroop Colour 41.5 11.3 (n=6) 77 .6 12.1 (n=1 9) 50.001
Stroop Colour-Word 21.7 5.5 (n=6) 43 . 1 8.2 (n=1 9) 50.001
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progressive impairment in memory, verbal fluency, con-
ceptual shifting and response inhibition, as evidenced by
the latest scores either approaching or below the 5
th
percentile of healthy controls (Fig. 2C).
Retrospective evaluation of clinical findings
in 14 patients with MSTD
A summary of the information collected retrospectively on
this group of 14 affected individuals (numbers 11–24) is
presented in supplementary information, Table 3. The
average age at disease onset was 48.6 5.7 years (range
39–58 years) and the average age at death was 58.9 6.6
years (range 47–69 years). The mean disease duration was
10.4 5.7 years (range 1–21 years). Clinical data were
available on 12 subjects (numbers 11–22). The presenting
signs of disease are known for 11 individuals. Behavioural
abnormalities were the initial symptom in 8 individuals
(numbers 12, 13, 15–18, 20, 22). They were associated with
short-term memory loss in two cases (numbers 18, 22) and
with short-term memory loss and dysnomia in four cases
(numbers 13, 15–17). Two siblings (brother and sister,
numbers 11, 14) presented with an atypical progressive
supranuclear palsy (PSP)-like syndrome characterized by
dizziness, pressure-like headaches, neck stiffness and
postural imbalance (Litvan et al., 1996). In addition,
subject number 11 reported episodes of tachycardia,
increased perspiration, swallowing difficulties, sleep dis-
order and urinary incontinence. Subject number 14 also
Fig. 2 Longitudinal measurement of brain (A) and ventricular
(B) volumes in five patients with MSTD and one asymptomatic
m u t a t i o nc a r r i e r .S u b j e c t s1 ,2 ,3a n d9p r e s e n t e dw i t hF T D ,
whereas subject 7 presented with disequilibrium and memory loss.
Progression of cognitive decline in the unaffected mutation carrier
is shown in table (C). ‰=5th percentile of healthy controls.
 =in bold, performance below the 5th percentile of controls.
#=scores are expressed in seconds.
Table 3 Distribution and severity of neuronal loss and
gliosis in the MSTD patients
Intermediate
disease duration
Long disease
duration
Neuronal
loss
Gliosis Neuronal
loss
Gliosis
Superior/middle frontal gyri ++ + +++ ++
Superior/middle temporal gyri ++ + +++ ++
Superior parietal lobe ^ ^ ++ +
Occipital cortex ^ ^ + +
Cingulate gyrus ++ + +++ +++
Insular cortex ++ + +++ +++
Hippocampus CA 1^ 4 + + + +
Dentate gyrus + + + +
Entorhinal cortex ++ + +++ ++
Amygdala ++ ++ +++ +++
Caudate nucleus ++ ++ +++ +++
Putamen ++ ++ +++ +++
Globus pallidus + + ++ ++
Substantia innominata + + ++ ++
Thalamus ^ ^ + +
Subthalamic nucleus ^ ^ + +
Hypothalamus ^ ^ + +
Cerebellar cortex ^ ^ + ^
Dentate nucleus ^ ^ + ^
Substantia nigra +++ + +++ ++
Oculomotor nucleus ^ ^ ++ +
Locus coeruleus ++ ^ +++ ++
Motor dorsal nucleus vagus ++ ^ +++ ++
Hypoglossal nucleus + ^ + +
Vestibular nuclei + ^ + +
Inferior olivary nucleus + ^ ++ +
+=mild, ++=moderate, +++=severe.
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number 21 presented with memory loss only. Over time,
10 subjects (numbers 12, 13, 15–22) developed a full
frontotemporal syndrome with behavioural alterations and
language deficits, leading to memory loss and late mutism.
Dizziness and neck stiffness were the predominant early
symptoms in subject numbers 11 and 14. Unsteadiness and
light-headedness were initially experienced in association
with rapid turning of the head; they became more frequent
and severe later on and ended up being continuous. To
reduce discomfort, both patients required proper adjust-
ment when sitting and could not use a car because of severe
motion sickness. They experienced neck muscle spasms, as
well as numbness and tingling sensations in hands, arms
and shoulders; grip strength and coordination were also
reduced. On physical examination, they had increased
muscle tone, particularly in the neck, as well as hyperactive
deep tendon reflexes. They experienced weakness of hand
muscles and, to a lesser extent, upper and lower extremities,
in the absence of atrophy and visible fasciculations. The
Hoffmann sign was present bilaterally, but no Babinski sign
was noted. Electromyography revealed signs of denervation
at multiple levels of the cervical spinal cord and scattered
fasciculations of hand muscles. Mild intentional tremor and
impaired alternating movements were noted during the
finger-to-nose test. Both patients exhibited limitation of
neck extension, reduced superior gaze, pursed lips and
swallowing difficulties. Sensory findings were normal.
Subject number 11 died of aspiration pneumonia almost
1 year after disease onset without displaying cognitive
alterations. Subject number 14 became unable to walk and
developed resting and intentional tremor, mild global
cognitive decline, reduced verbal fluency and naming. She
died suddenly 6 years after disease onset.
Data from a neurological evaluation were available for 9
of the 14 patients. Parkinsonism was the most commonly
reported finding, followed by frontal lobe signs, incon-
tinence, dysphagia, dizziness and signs of upper and/or
lower motor neuron dysfunction. Eye movement abnorm-
alities, sleep disturbance and paresthesias were noted less
commonly.
Summary of clinical data
For this group of patients with MSTD, the average age
of disease onset was 48.1 5.3 years (n=24, range 39–58
years) and the mean age at death 59.2 6.8 years (n=16,
range 47–69 years). The mean disease duration was
10.6 5.4 years (n=16, range 1–21 years). Clinical
presentation was that of bv-FTD in 17 individuals. Five
patients had a pure frontal syndrome, seven patients
presented with additional short-term memory impairment
and five with short-term memory impairment and
dysnomia. Three individuals presented with dizziness (two
of these patients also had early memory deficits). One
subject presented with an isolated short-term memory
deficit. Over the course of the disease, a diagnosis of FTD
was made in 20 patients. An atypical PSP-like presentation
(numbers 11, 14) and the lack of sufficient information
(numbers 23, 24) precluded a clinical diagnosis of FTD in
four individuals. Data from a neurological evaluation were
available for 19 patients. Parkinsonism was the most
common feature (12 patients), followed by incoordination
(eight patients), frontal lobe signs (eight patients), sleep
disturbances (seven patients), eye movement abnormalities
or a PSP-like syndrome (six patients), dysphagia (five
patients), signs of motor neuron disease (four patients) and
paresthesias (two patients).
Neuroimaging
As depicted in Fig. 3, the seven MSTD patients studied in
the early stages of disease with MRI and VBM (numbers 1,
2, 3, 4, 6, 8, 9) had a statistically significant loss of total
grey matter volume and increased CSF volume when
compared to 19 controls (P50.05), with the white matter
volume not being significantly different between the two
groups (see supplementary information, Table 4, for the
stereotactic locations of the most significant grey matter
loss). As shown in Fig. 4, the most significant focal points
of large clusters of grey matter loss occurred bilaterally in
medial temporal lobe (hippocampus/uncus; panels 2, 4),
opercular cortex and insular cortex (panel 3). With a
false discovery rate-corrected threshold (P50.05), these
clusters covered a large expanse of the anterior cingulate
gyrus (panel 1), the head of the caudate nucleus (panel 3)
and the posterolateral orbitofrontal cortex (panel 4). Grey
matter loss was also in evidence in the thalamus
(panels 1, 2).
Figure 5 illustrates the progression of whole brain
atrophy and ventricular enlargement in patient number 3.
Three years after disease onset, atrophy was particularly
evident at the level of superior frontal and cingulate gyri,
anterior temporal lobe, hippocampus and parahippocampal
gyrus (Fig. 5A). Seven years after disease onset, atrophy
had become more severe in frontal and temporal lobes
and the lateral ventricles were now markedly enlarged
especially in their anterior portion (Fig. 5B). In this
subject with severe behavioural abnormalities, the right
cerebral hemisphere was consistently more atrophic than
the left.
Longitudinal changes in 5 symptomatic patients (num-
bers 1, 2, 3, 7, 9) and the asymptomatic mutation carrier
are illustrated in Fig. 2. For affected mutation carriers,
the average changes in WBV and VV were  34.1ml/year
(2.47% decrease per year) and +7.46ml/year (11.87%
increase per year), respectively. They were  19.9ml/year
(1.38% decrease per year) and +4.07ml/year (8.57%
increase per year) for the unaffected mutation carrier.
Interestingly, in the first 2 years of this subject’s examina-
tion, we observed an average change in WBV and VV
of  7.2ml/year (0.47% decrease per year) and +2.4ml/year
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5 years of this subject’s follow-up, the average change
in WBV and VV were  26.3ml/year (1.83% decrease
per year) and +4.9ml/year (9.47% increase per year),
respectively.
Neuropathology
A case with a short disease duration (1year)
Formalin-fixed, paraffin-embedded blocks of cerebral
cortex, hippocampus, parahippocampal gyrus, medulla
and spinal cord were available for subject number 11 who
had suffered from an atypical PSP-like syndrome rather
than from FTD. The cerebral cortex showed mild loss of
neurons, gliosis and microvacuolar changes in the second
cortical layer. More severe neuronal loss and gliosis were
noted in hippocampus and parahippocampal gyrus. Tau-
immunoreactive neurons and neuropil threads were seen
in dentate gyrus, CA, subiculum and entorhinal cortex.
Occasional astrocytic plaques were observed in the
entorhinal cortex. In contrast, numerous coiled bodies
were present in subcortical white matter of the parahippo-
campal gyrus. Only a few tau-positive neurons and
neurofibrillary tangles were observed in the neocortex. In
the medulla, neuronal loss was moderate in the dorsal
motor nucleus of the vagus nerve, the hypoglossal nucleus,
the nucleus ambiguus and the inferior olivary nucleus, as
well as, to a lesser extent, in the vestibular nuclei and the
intermediate reticular zone. Nerve cells displayed tau-
immunoreactive inclusions and occasional neurofibrillary
tangles. Tau-immunoreactive neuropil threads were also
noted. In the anterior horn of the cervical and thoracic
spinal cord, mild to moderate nerve cell loss was observed.
Neurons in lamina IX displayed tau-immunoreactive
granular deposits. Abundant tau-immunoreactive neurites
and grain-like deposits, as well as occasional neurons,
were also present in lamina VII. The corticospinal tracts
Fig. 3 Grey matter (A), white matter (B)a n dC S F( C)v o l u m e s
in MSTD patients in the early stages of disease (case numbers
1, 2, 3, 4, 6, 8,9).The average disease duration was 2.1 1.0
years (n=7).Volumes were compared with those of age-
and gender-matched controls (n=19).Grey matter volume
was significantly reduced and CSF volume increased
(P50.05) in the MSTD patients, with no change in white
matter volume.
Table 4 Distribution and number of sarkosyl-insoluble tau
filaments in brain and spinal cord of six MSTD patients
S u b j e c t n o . 251 4 1 7 2 0 2 1
F r o n t a l c o r t e x + ++ +0 + + + + + +
Frontal white matter +++ +++ +/  ++ +++ ++
Temporal cortex +++ ++ 0 ++ +++ ++
Parietal cortex + + + n.d. + +
Parietal white matter ++ + n.d. ++ +++ n.d
Occipital cortex +/  +0+ n . d + /  
Occipital white matter + n.d. + n.d. + n.d
Hippocampus/parahippocampus ++ n.d. n.d + n.d. n.d.
Caudate/putamen ++ ++ + ++ + ++
T h a l a m u s +++ /   ++ +
C e r e b e l l u m 000 0 00
Spinal cord n.d. n.d. n.d. n.d. + n.d.
+/ =51 filament/grid square; +=1^14 filaments/grid square;
++=15^40 filaments/grid square; +++=440 filaments/grid
square; n.d.=not determined.
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unremarkable.
Cases with an intermediate disease duration (5^9 years)
Six cases (numbers 2, 13–17) belong to this group
(Table 1), five of whom had suffered from FTD. Case
number 14, who had presented with an atypical PSP-like
syndrome, is discussed separately. Macroscopic examination
revealed moderate, symmetric atrophy of the frontal and
temporal lobes, which was most prominent at the level of
the temporal pole and the parahippocampal gyrus. Caudate
nucleus and amygdala were the most atrophic among the
subcortical nuclei. The substantia nigra was depigmented,
while the locus coeruleus was not affected in all cases.
The bulk of the centrum semiovale was reduced, with
frontal and temporal horns of the lateral ventricles being
greatly enlarged. The histological changes are summarized
in Table 3. Neuronal loss mostly affected cortical layers II,
III, V and VI. Gliosis was particularly evident at the level
of the junction between cortical grey and white matter.
Spongiosis of the second cortical layer was a common
finding. Ballooned neurons were detected in the cerebral
cortex of three cases (numbers 13, 16, 17).
The distribution and severity of tau pathology are
summarized in Fig. 6A and exemplified in Fig. 7.
In neocortex, tau-immunoreactive deposits were most
abundant in neurons of layers II, III, V and VI (Fig. 8A
and B). They were also rarely noted among large pyramidal
Fig. 4 Heat map showing the patterns of grey matter loss in MSTD patients in the early stages of disease (combined data from case
numbers1, 2, 3, 4, 6, 8,9).The most significant clusters of grey matter atrophy were present in the medial temporal cortex (hippocampus/
uncus, panels 2 and 4), the opercular cortex and the insular cortex (panel 3). Additional areas of significant loss of grey matter were in
anterior cingulate gyrus (panel1), thalamus (panels1and 2), the head of the caudate nucleus (panel 3) and posterolateral orbitofrontal
cortex (panel 4). Displayed threshold: P50.05, false discovery rate-corrected.
Fig. 5 MRI scans of MSTD case number 3 recorded at ages 45 [3 years after disease onset (A)] and 49 years [7 years after disease onset
(B)].The patient died aged 50. Severe cortical and subcortical atrophy is evident in (A), particularly at the level of superior frontal and
cingulate gyri, anterior temporal lobes, hippocampus and parahippocampal gyrus. Marked progression of frontal and temporal lobar
atrophy, as well as severe ventricular enlargement, are evident in (B). Note that the right cerebral hemisphere is more atrophic than the
left. Images are in radiological orientation.
80 Brain (2008),131,7 2 ^8 9 S. Spina et al.neurons of the motor cortex. Most neuronal inclusions had
a granular appearance, while neurofibrillary tangles (NFTs)
were only occasionally seen in temporal cortex, parahippo-
campal gyrus, subiculum and amygdala (Fig. 8F). Abundant
grain-like neuropil threads were observed in frontal and
temporal cortices, hippocampus and subiculum. Tau-
positive astrocytic inclusions were present in the cerebral
cortex of all subjects with an intermediate disease duration,
with tufted astrocytes and astrocytic plaques being present
in subjects 2 and 17 (Figs. 8G and 9B). Tufted astrocytes
were more commonly noted in frontal and insular
cortices and in caudate/putamen. Astrocytic plaques were
mostly detected in frontotemporal and entorhinal cortices.
A consistent finding was the presence of numerous coiled
bodies in frontal, temporal and parietal lower cortical layers
and subcortical white matter, as well as in corpus callosum,
centrum semiovale, internal and external capsules and
descending fibers of the striatum (Fig. 9D). Tau deposits in
brainstem were limited almost entirely to nerve cells, either
in a granular cytoplasmic form, or as neuropil threads.
NFTs were rare.
Subject number 14 presented with an atypical PSP-like
syndrome and developed mild cognitive decline in the last
years of life. Pathologically, a small number of tau-
immunoreactive neurons was present in frontal, temporal
and parietal cortices and sparse coiled bodies in subcortical
Fig. 6 Distribution and severity of tau pathology in cerebrum and brainstem of MSTD patients who presented with FTD. (A)Casesof
intermediate disease duration (numbers 2,13,15,16,17). Subject number14, who presented with an atypical PSP-like syndrome, was
excluded. (B)cases of long disease duration (numbers 5,19, 20, 21, 22, 23, 24). Abbreviations: III=oculomotor nucleus; X=dorsal motor
nucleus of the vagus nerve; XII=hypoglossal nucleus; A1/C1=noradrenaline and/or adrenaline cells; AG=ambiens gyrus; AMB=nucleus
ambiguus; BSC=superior colliculus; CG=cingulate gyrus; CP =cerebral peduncle; DMN=deep mesencephalic nucleus; DRN=dorsal
raphe nucleus; DTN=dorsal tegmental nucleus; Ent=entorhinal cortex; FUG=fusiform gyrus; GRN=gigantocellular reticular nucleus;
ICP=inferior cerebellar peduncle; IG=insular gyrus; ION=inferior olivary nucleus; IRN=intermediate reticular nucleus; ITH=inferior
temporal gyrus; LC=locus coeruleus; LDTN=laterodorsal tegmental nucleus; LFP=longitudinal fibres of the pons; LPGN=lateral
paragigantocellular nucleus; LRN=lateral reticular nucleus; ME5=mesencephalic trigeminal nucleus; MFG=middle frontal gyrus;
MGN=medial geniculate nucleus; ML=medial lemniscus; MRN=median raphe nucleus; MTG=middle temporal gyrus; MVe=medial
vestibular nucleus; P=pyramidal tract; PAG=periaqueductal grey; PCF=pontocerebellar fibres; PCL=paracentral lobule;
PCRN=parvocellular reticular nucleus; PMRN=paramedian raphe nucleus; PN=pontine nuclei; PoG=postcentral gyrus; POP=parietal
operculum; PPTN=pedunculopontine tegmental nucleus; PrG=precentral gyrus; PRNo=pars oralis of pontine reticular nucleus;
PUL=pulvinar; RN=red nucleus; ROb=raphe obscurus nucleus; SCP=superior cerebellar peduncle; SFG=superior frontal gyrus;
SNc=substantia nigra, pars compacta; SNr=substantia nigra, pars reticulata; SP5=spinal trigeminal nucleus; SpVe=spinal vestibular
nucleus; STG=superior temporal gyrus.
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motor cortex were fewer than in controls, the
remaining ones occasionally displaying granular tau-
immunoreactive deposits. A few NFTs were seen in tem-
poral cortex. Sparse tau-immunoreactive neurons and
neuropil threads were also present in the CA and,
more extensively, in subiculum and entorhinal cortex.
A much greater burden of tau deposits was observed in
subcortical nuclei and in brainstem. Abundant tau-
immunoreactive nerve cells and tufted astrocytes were
present in caudate/putamen. The subthalamic nucleus
contained many tau-immunoreactive nerve cells
and occasional NFTs. In brainstem, abundant tau-
immunoreactive nerve cells and neuropil threads were
seen in substantia nigra, periaqueductal grey, oculomotor
nucleus, reticular formation, locus coeruleus and raphe
nuclei. In the spinal cord, moderate nerve cell loss and
gliosis were observed in the anterior horn. Residual neurons
in lamina IX were strongly tau-immunoreactive. Abundant
tau-positive nerve cells and neuropil threads were also
present in lamina VII. Sections of the corticospinal tract,
at the level of midbrain, pons, medulla and spinal cord,
revealed mild loss of axons and myelin as well as presence
of a limited number of CD68-immunoreactive macrophages
and microglial cells.
Immunohistochemistry for TDP-43 was carried out on
sections of frontal and temporal cortices, hippocampus and
medulla from subject numbers 2 and 14, as well as spinal
cord from subject 14: no TDP-43-immunoreactive deposits
were observed.
Cases with a long disease duration (12^21years)
Seven cases (numbers 5, 19–24) belong to this group
(Table 1), all of whom had suffered from FTD. Severe
knife-edge atrophy was observed in superior frontal, middle
frontal, orbitofrontal, superior temporal and anterior
cingulate gyri. Severe atrophy of the hippocampus and
parahippocampal gyrus was also noted. The caudate
nucleus was markedly atrophic, with a concave appearance
of the medial border of its head in most cases. Among the
Fig. 7 Immunohistochemistry for phosphorylated tau in coronal
sections from a case of MSTD of long disease duration.The
sections were taken at the level of the anterior (A)a n dp o s t e r i o r
(B) hippocampus of case number19. Marked atrophy is present
at the level of the superior frontal gyrus and the insular cortex
(particularly in their most anterior portions), the cingulate
gyrus, the middle and inferior temporal gyri, the hippocampus
and the parahippocampal gyrus. Note the extensive dilatation
of the lateral ventricle and the severe reduction of the corpus
callosum (most prominent in the anterior portion).The body of
the caudate nucleus is greatly reduced. Note the corresponding
distribution of tau pathology in cortex and subcortical white
matter, with partial sparing of the postcentral gyrus and the
superior temporal gyrus (in B). Anti-tau antibody=AT8. Scale
bars: 0.5cm.
Fig. 8 (A, B) Abundant tau-immunoreactive neurons and neuropil
threads in layers II, IVand Vof the cingulate gyrus (A) and layers II
and Vof the temporal cortex (B). (C) Numerous tau-positive
neurons and grain-like threads, as well as occasional tau-
immunoreactive astrocytes, in the pyramidal layer of hippocampal
sector CA1. (D) Many perinuclear neuronal tau deposits in the
granule cell layer of the dentate gyrus and a few tau-positive
astrocytes in the molecular layer of the dentate gyrus. (E)
Granular tau-immunoreactive neuronal deposits and occasional
neurofibrillary tangles in the substantia innominata. (F) A nerve
cell from frontal cortex with granular cytoplasmic tau immuno-
reactivity. (G) A tufted astrocyte in frontal cortex. (H)Ac o i l e d
body in the striatal white matter. All the sections are from the
brain of MSTD case number 5. Anti-tau antibody=PHF1. Scale
bars: A, B,C=50mm; D, E=10 mm; F, G, H =5 mm.
82 Brain (2008),131,7 2 ^8 9 S. Spina et al.remaining subcortical nuclei, only the thalamus was
relatively spared on gross examination. Substantia nigra
and locus coeruleus were severely depigmented. Centrum
semiovale and corpus callosum were further reduced in
bulk compared to cases with an intermediate disease
duration, and the entire ventricular system was extensively
dilated.
The histological findings are summarized in Table 3.
Spongiosis of the upper cortical layers was commonly
observed in frontal, temporal, entorhinal and, to a lesser
extent, parietal cortices. Ballooned neurons were occasion-
ally noted in the frontal and parietal cortices of patient
numbers 19, 21 and 24. The distribution and severity of tau
pathology are described in Fig. 6B. Tau-immunoreactive
neurons and neuropil threads were frequently observed
in neocortical layers II, III, V and VI. A few flame-
shaped NFTs were also seen. In the primary motor
cortex, occasional large pyramidal neurons displayed tau-
immunoreactive deposits. Tufted astrocytes were detected
in the frontal, temporal and cingulate cortices of patient
numbers 5, 19, 20, 21 and 24. Astrocytic plaques were
observed in the frontal, temporal and parietal cortices of
cases 5, 19 and 21. The extent of pathology in the
hippocampus varied among cases, with some displaying
numerous tau-immunoreactive neurons and neuropil
threads in the dentate gyrus and CA, and others presenting
only a few tau-positive neurons in CA1 (Fig. 8C and D).
Many coiled bodies were seen in lower cortical layers,
subcortical white matter, internal capsule, corpus callosum
and centrum semiovale. Abundant tau-immunoreactive
neurons and neuropil threads were present in substantia
nigra, reticular formation and anterior horn of the spinal
cord. NFTs were detected in periaqueductal grey, reticular
formation and raphe nuclei of most cases. Several patterns
of tau pathology were observed in spinal cord. Subject
number 19 displayed similar changes to those described
above for patients 11 and 14. The spinal cord of subject
number 20 was characterized by the involvement of lamina
VII, with weaker tau labelling of motor neurons (Fig. 10C
and D). Minimal loss of axons and myelin was observed in
Fig. 9 (A) Tau-immunoreactive neurons and grain-like threads in
the cingulate gyrus. (B) Tau-positive astrocytic plaque in the
temporal cortex. (C, D) Tau-immunoreactive coiled bodies in
temporal subcortical white matter (C) and corpus callosum (D).
(E) Severe neuronal loss, gliosis and abundant tau-positive neurons
and neuropil threads in the substantia nigra. (F,G)T a u - i m m u n o -
reactive nerve cells in the oculomotor nucleus (F) and the locus
coeruleus (G). (H) Tau-immunoreactive neurons and grain-like
threads in the anterior horn of the spinal cord.The sections in
(A^G) are from the brain of MSTD case number 2.The spinal
cord section in (H) is from MSTD case number14. Anti-tau
antibodies=RD4 specific for 4-repeat tau isoforms (A,C, D, E, F,
G, H) and AT8 (B). No specific staining was obtained when anti-
body RD3, which recognizes tau isoforms with three repeats, was
used. Scale bars: E=25mm; A, F, G, H=10mm; B,C,D= 5 mm.
Fig. 10 (A, B) Antibodies RD3 (specific for tau isoforms with
three repeats) and RD4 (specific for tau isoforms with four
repeats) were used. Neurons and neurofibrillary tangles in the
frontal cortex of subject number 20 were immunolabelled by RD3
(A) and RD4 (B): this subject constitutes an exception, since no
other affected family member displayed such an extent of 3-repeat
tau pathology in the cerebral cortex, in conjunction with the
4-repeat tau pathology typical of MSTD.Grain-like deposits in the
neuropil were selectively labelled by RD4. (C, D)S p i n a lc o r df r o m
subjects number19 (C) and 20 (D) stained with RD4. Note the
presence of extensive tau-immunoreactive deposits in neurons
and threads in laminaeVII and IX in (C) and the predominant
involvement of lamina VII, with only weak immunoreactivity of
motor neurons in (D). Scale bars: 20mm.
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number 21, laminae VII and IX were overall equally tau-
immunoreactive. Only patient number 5 displayed
Alzheimer-type pathology consisting of neuritic plaques in
the neocortex (CERAD age-related plaque score B) and
NFTs in transentorhinal and entorhinal cortex (Braak
stage 2). Subject number 20 presented with rare clusters
of Ab-immunoreactive diffuse plaques in the cerebral cortex
and mild amyloid angiopathy of leptomeningeal vessels.
Immunohistochemistry for TDP-43 was carried out on
sections of frontal and temporal cortices, hippocampus and
spinal cord from subject 20: no TDP-43-immunoreactive
deposits were observed.
Tau immunohistochemistry
Neuronal and glial tau deposits were intensely labelled by
antibodies AT8, PHF1 and AT180. Antibody PG5 strongly
stained cortical neurons and astrocytes, with weaker label-
ling of neuropil threads in dentate gyrus and molecular
layer of the hippocampus. Antibody 12E8 labelled
the majority of tau-immunoreactive neurons and oligoden-
drocytes in cortex, but failed to stain deposits in astrocytes.
Weaker labelling was obtained with antibody CP3 and
almost no labelling was observed with antibodies AT100,
AT270 and Alz50. For the vast majority of cases,
immunohistochemistry with antibodies RD3 and RD4
revealed that the neuronal and glial inclusions were
composed solely of 4-repeat tau. The major exception was
case number 20 with abundant RD3-immunoreactive nerve
cell deposits in the substantia nigra and in layers II, V
and VI of the cerebral cortex. RD3 labelled virtually all
flame-shaped and perinuclear NFTs that were also RD4-
immunoreactive (Fig. 10A and B). In addition, a few tau-
immunoreactive neurons and flame-shaped NFTs in the
neocortex of patient number 5, as well as a few neurons in
the locus coeruleus of case number 2, were reactive with
antibody RD3.
Genetic analysis and phenotypic correlation
A (g) to (a) transition at position +3 of the 50 splice site of
intron 10 of Tau was present in 30 of the 59 individuals
investigated. At the time of writing, 24 of these had
developed symptoms of MSTD (Table 1, Fig. 1). The Tau
haplotype was determined in 29 mutation carriers; the
H1H2 genotype was found in 20 individuals and the H2H2
genotype in nine individuals. To date, clinical symptoms
and signs of MSTD have been observed in 16 mutation
carriers with the H1H2 genotype and in seven mutation
carriers with the H2H2 genotype. Nine mutation carriers
with the H1H2 genotype and six mutation carriers with the
H2H2 genotype have died. The mean age of onset was 48.5
years regardless of genotype. The mean disease duration
was 9.7 6.3 years for the H1H2 group and 10.3 2.2 years
for the H2H2 group. Tau sub-haplotypes were determined
in 18 mutation carriers. Interestingly, subject numbers
11 and 14, who developed an atypical PSP-like syndrome
instead of bv-FTD, inherited the same H1C Tau haplotype
with the wild-type allele. The same was true of subject
number 8, who suffered from bv-FTD (see supplementary
information, Table 5). The ApoE genotype was determined
in 23 mutation carriers. An e3/e3 genotype was observed in
18 individuals; two individuals had an e2/e3 genotype and
three had an e3/e4 genotype.
Biochemistry and electron microscopy
Sarkosyl-insoluble material was prepared from a total of 54
brain areas of six individuals with MSTD and from a total
of 20 brain areas of two unaffected family members lacking
the +3 mutation in intron 10 of Tau. The spinal cords of
cases 20 and 21 were also used. Three cases (numbers 2, 14,
17) were of intermediate disease duration and three cases
(numbers 5, 20, 21) were of long disease duration. By
immunoelectron microscopy, tau filaments from cases 2, 5,
14, 17 and 21 had a twisted ribbon or a half ribbon
appearance (Fig. 11A–D and H). In brain and spinal cord
of case 20, in addition to twisted ribbons and half ribbons,
a substantial proportion of tau filaments consisted of
Alzheimer-type paired helical and straight filaments (PHFs
and SFs) (Figs 11E–G, I and 12). No tau filaments were
detected in the sarkosyl-insoluble material prepared from
brain regions of two unaffected members of the pedigree.
The distribution and relative abundance of tau filaments
are shown in Table 4. Cases 2, 5, 17, 20 and 21 showed a
substantial filament load in frontal and temporal lobes, with
smaller numbers of filaments in parietal and occipital lobes.
Filaments were particularly abundant in frontal and parietal
white matter, probably reflecting the presence of abundant
glial cell inclusions. Where examined, numerous filaments
were present in caudate/putamen, hippocampus, parahip-
pocampus, thalamus and spinal cord. The cerebellum
was devoid of tau filaments. Overall, the distribution
and relative abundance of tau filaments in 5 cases were
consistent with a disease process prominently affecting the
frontal and temporal lobes of the cerebral cortex. This was
not true of case number 14, who lacked tau filaments in
frontal and temporal lobes and had a filament load that was
less severe than that of the other five cases. Clinically,
individual number 14 did not have FTD, but presented
with an atypical PSP-like syndrome.
By Western blotting of sarkosyl-insoluble tau extracted
from brain, five cases (numbers 2, 5, 14, 17, 21) showed
two major pathological tau bands of 64 and 68kDa, with a
minor tau band of 72kDa being visible in some cases
(Fig. 11J). The same was true of sarkosyl-insoluble tau from
the spinal cord of case number 21 (data not shown). In
contrast, immunoblots of sarkosyl-insoluble tau from brain
and spinal cord of case number 20 displayed three major
tau bands of 60, 64 and 68kDa, as well as the minor 72kDa
band, in keeping with the presence of PHFs and SFs by
immunoelectron microscopy (Figs 11J and 12). The 60kDa
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pathological tau bands were detected in the equivalent brain
areas from two unaffected members of the MSTD kindred.
Discussion
The MSTD family was the first known kindred with a +3
mutation in the intron following exon 10 of Tau
(Spillantini et al., 1998b). Subsequently, two additional
kindreds with this mutation were identified (Tolnay et al.,
2000; Neumann et al., 2005). Here, we present a
comprehensive study of 24 affected individuals of the
MSTD kindred. Age at onset of disease ranged from 39 to
58 years and the disease duration was 1–21 years. The
bv-FTD was the most common clinical presentation in the
MSTD family. It was seen in 17 of the 21 affected
individuals for whom sufficient clinical information was
available. Five of these patients had a pure behavioural
syndrome, with 12 patients also presenting with memory
impairment. The second most common clinical presenta-
tion was an atypical PSP-like syndrome, which was present
in two individuals, one of whom also had memory deficits.
Another patient presented with severe postural imbalance;
however, coexistent Me ´nie `re’s disease may have contributed
to the severity of symptoms. This patient also presented
with memory loss and developed personality changes, as
well as dysexecutive symptoms. One patient presented with
an isolated short-term memory deficit. These findings
indicate that memory loss is a common presenting sign
in MSTD.
Early-stage MSTD patients with bv-FTD, studied by
MRI-based VBM and compared to age-matched controls,
had the most extensive grey matter loss in the hippocam-
pus, parahippocampal gyrus and frontal operculum/insular
cortex of the right hemisphere. This pattern strongly
resembles that observed in a group of FTDP-17 subjects
with the exon 10+16 Tau mutation (Whitwell et al., 2005).
To a lesser extent, MSTD patients also displayed grey
matter loss in the anterior cingulate gyrus, head of the
caudate nucleus, posterolateral orbital cortex and insular
cortex bilaterally. These data suggest a pattern of early grey
matter loss in limbic, cortical and subcortical regions,
which have extensive prefrontal-frontal connections. This
was reflected in the patients’ early symptoms, which were
marked by behavioural changes and memory loss, sugges-
tive of prefrontal and hippocampal dysfunction. Bilateral
atrophy of the orbitofrontal and insular cortices, as well as
impaired metabolic activity of the same regions, have
previously been reported in FTD in association with
disinhibition (Rosen et al., 2002; Peters et al., 2006).
Fig. 11 Immunoelectron microscopy and immunoblotting of sarkosyl-insoluble tau from brain of MSTD cases number 2,5,14,17 ,20 and 21.
(A) Twisted ribbon from hippocampus of case number 2. (B) Twisted ribbon from temporal cortex of case number 5. (C)T w i s t e dr i b b o n
from parietal cortex of case number14. (D) Twisted ribbon from frontal white matter of case number17 . (E) Half ribbon from thalamus of
case number 20. (F) Paired helical filament from thalamus of case number 20. (G) Straight filament from frontal cortex of case number 20.
(H) Twisted ribbon from putamen of case number 21. (I) Twisted ribbons [R], paired helical filaments [P] and straight filaments [S] in
parietal white matter of case number 20. (J) Immunoblotting of sarkosyl-insoluble tau from frontal white matter (cases 2, 5,17 , 20, 21) and
caudate/putamen (case14). All sixcases showed the presence of strong taubands of 64 and 68kDa molecular mass.For case number 20, an
additional band of 60kDa was also seen. Anti-tau antibody=BR134. Scale bar,100nm.
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with atrophy or impairment of the anterior cingulate gyrus
(Salmon et al., 2003; Liu et al., 2004; Williams et al., 2005).
In contrast, the early involvement of hippocampus and
parahippocampus observed in MSTD has not been
consistently seen in FTDP-17T or FTD generally.
Little is known about the progression of anatomical
changes in FTDP-17T along the disease course. In our
study, the longitudinal evaluation of brain volume revealed
a near linear increase in brain atrophy in affected mutation
carriers, similar to what has been described for two siblings
with the S305N mutation in Tau (Boeve et al., 2005). In an
MSTD asymptomatic mutation carrier followed for 7 years,
brain atrophy was slowly progressive for the first 2 years,
but has been increasing in a near linear fashion since. Brain
volume and rate of atrophy now approach those of affected
mutation carriers. This trend parallels that of the progres-
sive cognitive decline evidenced by neuropsychological
assessment. Performance on a test of verbal learning is
now below the fifth percentile of controls. Additional scores
on tests for verbal memory, verbal fluency and response
inhibition are now close to the cut-off of affected indi-
viduals. Several biomarkers have been proposed in order to
identify FTDP-17 disease onset (Alberici et al. 2004;
Arvanitakis et al., 2007). Our findings suggest the usefulness
of quantitative brain imaging for determining and predict-
ing disease onset in FTDP-17T.
A new finding emerging from this study is the
identification of individuals affected with a phenotypic
variant of MSTD, resembling an atypical PSP-like
syndrome. The observed clinical heterogeneity extends
knowledge derived from similar findings in other FTDP-
17T families (Bugiani et al., 1999) and further supports an
aetiological relationship between FTD and PSP (Kertesz,
2003). Previously, different mutations in Tau were also
found to give rise to atypical PSP-like syndromes (Delisle
et al., 1999; Stanford et al., 2000; Pastor et al., 2001;
Poorkaj et al., 2002; Ros et al., 2005; Van Swieten and
Spillantini, 2007). Genetic modifiers may have a strong
influence on the initial clinical presentation of disease in
the MSTD family. The mutation occurred on the back-
ground of at least one H2 Tau allele, with no statistically
significant differences in age at onset and disease duration
between mutation carriers with haplotypes H1H2 and
H2H2. This finding is consistent with the results of a
previous study (Baba et al., 2005). Since it has been shown
that specific H1 Tau sub-haplotypes are differently
associated with the risk to develop tauopathies (Pittman
et al., 2005), we analyzed Tau sub-haplotypes in our group
of MSTD individuals. Interestingly, the two subjects
(brother and sister), who presented with an atypical PSP-
like phenotype, were carriers of an H1C Tau haplotype
wild-type allele, which has been associated with an
increased risk to develop PSP (Pittman et al., 2005) and
increased expression of 4-repeat tau isoforms (Myers et al.,
2007). The synergistic effects of an H1C haplotype in the
wild-type allele and the exon 10+3 mutation in the
pathogenic allele may have played a role in giving rise to
the clinical presentation of atypical PSP in these two
siblings. However, a third subject with the H1C haplotype
in the wild-type allele did not develop signs of PSP. This
individual belongs to a different branch of the pedigree
from that of the two siblings and has thus a different
genetic background, suggesting that additional genetic
modifiers may also play a role. The small sample size
prevented us from investigating statistical correlations
between specific Tau sub-haplotypes and clinicopathologi-
cal findings. Since the large majority of affected subjects
was homozygous for the ApoE e3 allele, we were unable to
study the role of ApoE genotype as a genetic modifier of
MSTD.
Fig. 12 Immunoelectron microscopy and immunoblotting of
sarkosyl-insoluble tau from the spinal cord of MSTD case number
20. (A)T w i s t e dr i b b o n .( B)S t r a i g h tf i l a m e n t .( C) Paired helical
filaments. (D) Straight filament decorated with anti-tau antibody
BR134. (E) Paired helical filament decorated with BR134.
(F) Immunoblotting of sarkosyl-insoluble tau from the frontal
cortex of a case of sporadic Alzheimer’s disease (AD) and the
spinal cord of MSTD case number 20 using antibody BR133.The
abnormal tau bands of 60, 64, 68 and 72kDa molecular mass are
arrowed. Scale bar,100nm.
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at disease onset and in a total of 20 individuals along the
disease course. It was mostly characterized by naming
difficulties, stereotyped speech and reduced verbal fluency,
resulting in late mutism. Reduced verbal fluency and, to a
lesser extent, executive functioning have been reported as
the most consistent early feature of cognitive dysfunction in
FTDP-17T individuals (Van Swieten et al., 1999; Ferman
et al., 2003). Parkinsonism was only noted in the third year
of disease, with limb incoordination appearing in year 4,
and frontal release signs, eye movement disorders and sleep
abnormalities in year 5.
The neuropathological correlates of MSTD were investi-
gated in 14 patients, 12 of whom had suffered from bv-FTD
and two from atypical PSP. In cases with FTD of long
duration, atrophy of the frontotemporal lobes and the
cingulate gyrus was extensive, with less neurodegeneration
in parietal and occipital lobes. Hippocampal formation and
striatum were also severely affected, as were substantia
nigra, locus coeruleus and dorsal motor nucleus of the
vagus nerve.
The involvement of selected brainstem nuclei may
explain some of the clinical features of MSTD. Thus,
sleep-wake cycle disruption (7/19 subjects) may have
resulted from neurodegeneration in locus coeruleus, raphe
nuclei, pedunculopontine tegmental nucleus, laterodorsal
tegmental nucleus and pontine reticular formation, as well
as in the limbic system, all regions known to be important
for sleep-wake cycle regulation (Sakurai, 2007).
Motor system pathology was characterized by mild cell
loss and tau pathology in giant pyramidal cells of
Brodmann area 4, as well as mild loss of axons and
myelin in the corticospinal tract. The spinal cord consis-
tently showed nerve cell loss in the anterior horn, similar to
what has been described for a case with the N279K
mutation in Tau (Slowinski et al., 2007). Vulnerability of
motor neurons to tau-induced neurodegeneration is also
supported by the phenotypes of some transgenic mouse
models of human tauopathies (Lewis et al., 2000; Allen
et al., 2002). Tau pathology was consistently detected in
neurons of lamina VII. In most cases, motor neurons in
lamina IX contained strongly tau-immunoreactive deposits.
However, in one case, lamina IX was free of deposits.
Additional studies are necessary to verify the existence of
a heterogeneous pattern of tau pathology in the spinal cord
of different MSTD patients. These findings may explain
the presence of pyramidal/motor neuron disease signs
in some patients and motor incoordination, possibly
secondary to pathology of different descending pathways
(e.g. reticulospinal and vestibulospinal), in others
(Schoenen and Grant, 2004).
Overall, the severity of neurodegeneration in MSTD was
proportional to disease duration. Cases with an atypical PSP-
like syndrome were of either short (1 year) or intermediate
(6 years) disease duration. They had much less pathology in
the cerebral cortex than cases with FTD, with similar changes
in subcortical areas. By immunohistochemistry, deposits
made of hyperphosphorylated tau protein were present in
neurons, astrocytes and oligodendrocytes in all affected brain
regions. Oligodendroglial inclusions were particularly
numerous in subcortical white matter in all cases, consistent
with our previous findings (Spillantini et al., 1997; Spillantini
et al., 1998a). In some cases, tufted astrocytes and astrocytic
plaques were also present.
Tau inclusions were mostly made of 4-repeat tau, in
keeping with the known effects of the +3 intronic mutation
on the splicing of exon 10 of Tau (Spillantini et al., 1998b;
Varani et al., 1999). Ultrastructurally, tau filaments had the
appearance of twisted ribbons or half ribbons, in line with
our earlier work (Spillantini et al., 1997). Relative filament
numbers correlated well with the level of tau staining in a
given brain region and the magnitude of neurodegeneration
therein. One case showed a large number of Alzheimer-type
PHFs and SFs, in addition to ribbon-like filaments. By
immunohistochemistry, tau inclusions in this case were
made of 3- and 4-repeat tau. By immunoblotting,
pathological tau bands of 60, 64, 68 and 72kDa were
present, as is the case in Alzheimer’s disease (Goedert et al.,
1992). However, unlike what is observed in Alzheimer’s
disease, the 60kDa band was weaker than the 64
and 68kDa bands, consistent with the presence of more
ribbon-like filaments than PHFs and SFs. This case
constitutes an exception to the rule that the overexpression
of human 4-repeat tau isoforms results in the formation of
inclusions made solely of 4-repeat tau (Goedert and
Spillantini, 2006; Van Swieten and Spillantini, 2007). The
mechanisms leading to the coexistence of filaments made of
4-repeat tau only and of all 6 tau isoforms remain to be
established.
In summary, this multidisciplinary and longitudinal
characterization of the MSTD kindred has provided new
insights into the neurodegenerative process: (i) mutation +3
in intron 10 of Tau can give rise to a clinical and
neuropathological picture of either FTD or atypical PSP;
(ii) Tau haplotype of the wild-type allele may act as a
genetic modifier of disease presentation; (iii) early-onset
memory loss and hippocampal atrophy are common
findings in MSTD; (iv) quantitative neuroimaging may
be useful in predicting disease onset in FTDP-17T;
(v) neurodegeneration in MSTD involves various neurolo-
gical systems, including prefrontal and limbic cortical/
subcortical regions, hippocampus, parahippocampus,
selected brainstem nuclei and spinal cord.
Supplementary material
Supplementary materials are available at Brain online.
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